11 June 2020 - Topical combination improving the sings and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis formulated with proprietary Prismatex technology.

Bausch Health Canada has announced that Health Canada has approved the use of Duobrii (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene) lotion, a topical prescription medicine indicated for improving the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis.

Read Bausch Health press release